From USD 390 million in 2022 to USD 1.5 billion by 2031, the worldwide artificial pancreas market is expected to rise at a CAGR of 18.2%. Currently, North America rules the market.
Rising diabetes rates globally and technology developments in continuous glucose monitoring and insulin delivery systems are driving fast expansion of the artificial pancreas market. Market growth is being driven by growing knowledge of the advantages of automated insulin delivery as well as by favorable reimbursement policies in developed nations. The combination of artificial intelligence and machine learning techniques is improving the accuracy and performance of these devices, therefore accelerating the expansion of the market.
Current Market Trend Integration of artificial intelligence and machine learning improves personalizing and device performance.
One important trend causing market expansion in artificial pancreas systems is the integration of artificial intelligence (AI) and machine learning algorithms. More exact glucose monitoring, insulin dosage, and tailored treatment plans made possible by these technologies allow for Learning from individual patient data, artificial intelligence-powered systems can adapt to particular physiological patterns and lifestyle choices. Improved glucose control, less hypoglycemia events, and better general diabetes patient outcomes follow from this. By processing enormous volumes of real-time data, artificial intelligence enables more complex prediction models and decision-support systems, hence improving the safety and efficiency of artificial pancreas devices. AI is predicted to become even more important in optimizing artificial pancreas performance and extending its capabilities as it develops.
Growing demand for automated insulin administration systems and a rising diabetes prevalence
The artificial pancreas industry is mostly driven by the rising worldwide diabetes prevalence. The International Diabetes Federation projects that by 2045 there will be 783 million adults living with diabetes. Artificial pancreas devices are being used in response to this increase in diabetes patients as well as the growing need for more efficient and handy diabetic treatment options. Among the several benefits these devices provide over conventional insulin treatment approaches are better glucose control, lower risk of complications, and more patient quality of life. Artificial pancreas systems help reduce the load of continuous diabetes treatment by automating insulin delivery depending on continuous glucose monitoring data, therefore addressing the problems of manual insulin administration. Artificial pancreas devices are predicted to be much in demand as knowledge of these advantages increases and technology develops.
Market Restraint : Limitation of the Market Limited access and high expenses prevent general acceptance.
Especially in underdeveloped nations and among lower-income groups, the great expense linked with artificial pancreas devices continues to be a major obstacle to general acceptance. For many patients, the initial outlay for these sophisticated gadgets plus continuous supplies and maintenance costs might be overwhelming. Furthermore restricting access to these cutting-edge technology are some areas' limited insurance coverage and reimbursement rules. The intricacy of artificial pancreas systems also requires specialized training for patients and healthcare professionals, which can be difficult to apply generally. These elements taken together contribute to limited accessibility, therefore impeding market expansion in some geographical locations and demographic sectors. Expanding the scope of artificial pancreas technology and realizing its whole market potential depend on addressing these cost and accessibility problems.
With better glucose control, closed-loop devices predominate in the market by device type
Currently ruling the artificial pancreas market are closed-loop systems, especially Control-to- Range (CTR) and Control-to- Target (CTT). These sophisticated gadgets automatically modify insulin delivery in real-time and constantly monitor blood sugar levels, therefore providing better glucose management. Closed-loop systems have been very popular among healthcare professionals and patients because their capacity to more nearly replicate the function of a healthy pancreas than other device kinds. With closed-loop devices, clinical trials have shown notable increases in time-in-range and decreased hypoglycemia episodes, therefore supporting their commercial predominance.
North America leads the market because of its advanced healthcare system and high diabetes frequency. Artificial pancreas market regional analysis
Currently holding the most market share, North America rules the artificial pancreas business. Strong payment rules, excellent healthcare infrastructure, and great diabetes prevalence help to explain this geographical dominance. Particularly the United States has been leading in the evolution and acceptance of artificial pancreas technologies. Major market participants, significant R&D investment, and a favorable legal environment have helped the artificial pancreas market in North America to grow rapidly. Furthermore driving market expansion in this area are rising awareness among patients and healthcare workers on the advantages of automated insulin delivery devices.
With an eye toward technological innovation and strategic alliances, fierce competition among important players defines the artificial pancreas industry. Leading corporations are extensively funding research and development to increase gadget performance, better user experience, and widen product ranges. Common approaches to improve market positioning are mergers, acquisitions, and alliances with diabetes management software companies and insulin producers. Regulatory approvals also help to define the competitive environment since businesses try to get clearances for new gadgets and enlarged indications. Competition is predicted to becoming more fierce as the market develops, which will inspire more creativity and maybe result in more reasonably priced and easily available artificial pancreas options.
Medtronic plc
Insulet Corporation
Tandem Diabetes Care, Inc.
Beta Bionics, Inc.
Bigfoot Biomedical, Inc.
Dexcom, Inc.
Diabeloop SA
Cellnovo Group SA
Tidepool
EOFlow Co., Ltd.
Ypsomed Holding AG
Roche Diabetes Care
1. INTRODUCTION
1.1. Market Definition
1.2. Study Scope
1.3. Currency Conversion
1.4. Study Period (2022- 2031)
1.5. Regional Coverage
2. RESEARCH METHODOLOGY
2.1. Primary Research
2.2. Secondary Research
2.3. Company Share Analysis
2.4. Data Triangulation
3. EXECUTIVE SUMMARY
3.1. Global Artificial Pancreas Market (2018 – 2022)
3.2. Global Artificial Pancreas Market (2023 – 2031)
3.2.1. Market Segment By Device Type (2023 – 2031)
3.2.2. Market Segment By Treatment Type (2023 – 2031)
3.2.3. Market Segment By End User (2023 – 2031)
3.2.4. Market Segment By Region (2023 – 2031)
4. MARKET DYNAMICS
4.1. Market Trends
4.1.1. Integration of AI and machine learning enhances device performance and personalization
4.1.2. Increasing focus on interoperability and device connectivity
4.1.3. Growing adoption of telemedicine for remote diabetes management
4.2. Market Drivers
4.2.1. Rising prevalence of diabetes and growing demand for automated insulin delivery systems
4.2.2. Technological advancements in continuous glucose monitoring
4.2.3. Supportive reimbursement policies in developed countries
4.3. Market Restraints
4.3.1. High costs and limited accessibility hinder widespread adoption
4.3.2. Concerns about cybersecurity and data privacy
4.4. Porter's Five Forces Analysis
4.4.1. Threat of New Entrants
4.4.2. Bargaining Power of Buyers/Consumers
4.4.3. Bargaining Power of Suppliers
4.4.4. Threat of Substitute Products
4.4.5. Intensity of Competitive Rivalry
4.5. Supply Chain Analysis
4.6. Pricing Analysis
4.7. Regulatory Analysis
4.8. Pipeline Analysis
5. BY DEVICE TYPE (MARKET VALUE (US$ MILLION) – 2022-2031*)
5.1. Threshold Suspended Device Systems
5.2. CTR Systems
5.3. CTT Systems
6. BY TREATMENT TYPE
6.1. Bi-hormonal
6.2. Insulin-only
7. BY END USER
7.1. Hospitals
7.2. Clinics
7.3. Home Care Settings
8. GEOGRAPHY
8.1. North America
8.1.1. United States
8.1.2. Canada
8.1.3. Mexico
8.2. South America
8.2.1. Brazil
8.2.2. Argentina
8.2.3. Rest of South America
8.3. Europe
8.3.1. Germany
8.3.2. United Kingdom
8.3.3. France
8.3.4. Italy
8.3.5. Spain
8.3.6. Russia
8.3.7. Rest of Europe
8.4. Asia-Pacific
8.4.1. China
8.4.2. Japan
8.4.3. India
8.4.4. Australia
8.4.5. South Korea
8.4.6. Rest of Asia-Pacific
8.5. Middle-East
8.5.1. UAE
8.5.2. Saudi Arabia
8.5.3. Turkey
8.5.4. Rest of Middle East
8.6. Africa
8.6.1. South Africa
8.6.2. Egypt
8.6.3. Rest of Africa
9. COMPETITIVE LANDSCAPE
9.1. Key Developments
9.2. Company Market Share Analysis
9.3. Product Benchmarking
10. SWOT ANALYSIS
11. COMPANY PROFILES
11.1. Medtronic plc
11.2. Insulet Corporation
11.3. Tandem Diabetes Care, Inc.
11.4. Beta Bionics, Inc.
11.5. Bigfoot Biomedical, Inc.
11.6. Dexcom, Inc.
11.7. Diabeloop SA
11.8. Cellnovo Group SA
11.9. Tidepool
11.10. EOFlow Co., Ltd.
11.11. Ypsomed Holding AG
11.12. Roche Diabetes Care
12. MARKET OPPORTUNITIES
By Device Type:
Threshold Suspended Device Systems
CTR Systems
CTT Systems
By Treatment Type:
Bi-hormonal
Insulin-only
By End User:
Hospitals
Clinics
Home Care Settings
By Region:
North America
Europe
Asia-Pacific
Latin America
Middle East & Africa
We at Aurorawave Intellects Market Report gives total market analysis that suit our customer business need and permit decision maker to run organizations without any problem. We have accomplished greatness in giving start to finish market research arrangements. Our detachment of industry specialists accumulate key data and get ready substance that lines up with our customer's business/specialty.
We at aurorawaveintellects.com offer mainly 3 types of licenses:
• Single User: Research Report copy can be distributed to a single user only
• Multi User: Research Report distribution is restricted up to 5 users.
• Corporate License :Research Report can be distributed across the company.
Based on the nature of the topic or research, the formats vary. The different formats of the report are as following:
• Word Document
• PPT
Following modes are available for making the payment:
• Online Payment (Visa Card, Master Card, Stripe)
• Razorpay
• Net Banking
• Bank Wire Transfer
Our customer service and research specialist team are available by phone and by email. Customer service hours are 24X7 Indian Standard Time (IST). You may reach us at:
• Email: info@aurorawaveintellects.com
• United Kingdom: ++91 7382742511
